Preparation of extended metaphase chromosomes from human cultured cells using a topoisomerase II inhibitor, ICRF-193

被引：2
|
作者：
Kohda, A [1 ]
Taguchi, H [1 ]
Okumura, K [1 ]
机构：
[1] Mie Univ, Fac Bioresources, Mol & Cellular Biol Lab, Tsu, Mie 5148507, Japan
来源：
BIOSCIENCE BIOTECHNOLOGY AND BIOCHEMISTRY | 2001年 / 65卷 / 05期
关键词：
chromosome preparations; fluorescence in situ hybridization; topoisomerase II inhibitor; HL60; HepG2;
D O I：
10.1271/bbb.65.1248
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Effects of ICRF-193, a topoisomerase II inhibitor, on metaphase chromosome preparations were examined. A short-time exposure of this drug to human HL60 cells in a suspension culture before harvest resulted in obtaining more extended metaphase chromosomes, The length, of chromosome 6 identified by fluorescence in situ hybridization was twice as long with this drug treatment. Together with effectiveness for adherent HepG2 cells, these results suggest that treatments with ICRF-193 provide a simple and reliable method for chromosome preparations from extended cultured metaphase cells.
引用
收藏
页码：1248 / 1251
页数：4
相关论文
共 31 条
  • [11] ICRF-193, an anticancer topoisomerase II inhibitor, induces arched telophase spindles that snap, leading to a ploidy increase in fission yeast
    Nakazawa, Norihiko
    Mehrotra, Rajesh
    Arakawa, Orie
    Yanagida, Mitsuhiro
    GENES TO CELLS, 2016, 21 (09) : 978 - 993
  • [12] Development of water-soluble prodrugs of the bisdioxopiperazine topoisomerase IIβ inhibitor ICRF-193 as potential cardioprotective agents against anthracycline cardiotoxicity
    Piskackova, Hana Bavlovic
    Jansova, Hana
    Kubes, Jan
    Karabanovich, Galina
    Vanova, Nela
    Kollarova-Brazdova, Petra
    Melnikova, Iuliia
    Jirkovska, Anna
    Lencova-Popelova, Olga
    Chladek, Jaroslav
    Roh, Jaroslav
    Simunek, Tomas
    Sterba, Martin
    Sterbova-Kovarikova, Petra
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [13] Casein kinase II-dependent phosphorylation of DNA topoisomerase II suppresses the effect of a catalytic topo II inhibitor, ICRF-193, in fission yeast
    Nakazawa, Norihiko
    Arakawa, Orie
    Ebe, Masahiro
    Yanagida, Mitsuhiro
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2019, 294 (10) : 3772 - 3782
  • [14] Development of water-soluble prodrugs of the bisdioxopiperazine topoisomerase IIβ inhibitor ICRF-193 as potential cardioprotective agents against anthracycline cardiotoxicity
    Hana Bavlovič Piskáčková
    Hana Jansová
    Jan Kubeš
    Galina Karabanovich
    Nela Váňová
    Petra Kollárová-Brázdová
    Iuliia Melnikova
    Anna Jirkovská
    Olga Lenčová-Popelová
    Jaroslav Chládek
    Jaroslav Roh
    Tomáš Šimůnek
    Martin Štěrba
    Petra Štěrbová-Kovaříková
    Scientific Reports, 11
  • [15] Chk1 is required for G2/M checkpoint response induced by the catalytic topoisomerase II inhibitor ICRF-193
    Robinson, Helen M. R.
    Bratlie-Thoresen, Sigrid
    Brown, Robert
    Gillespie, David A. F.
    CELL CYCLE, 2007, 6 (10) : 1265 - 1267
  • [16] A comparative study of genotoxic effects of anti-topoisomerase II drugs ICRF-193 and bufalin in Chinese hamster ovary cells
    Pastor, N
    Domínguez, I
    Mateos, S
    Cortés, F
    MUTATION RESEARCH-GENETIC TOXICOLOGY AND ENVIRONMENTAL MUTAGENESIS, 2002, 515 (1-2) : 171 - 180
  • [17] Different susceptibilities of postmitotic checkpoint-proficient and -deficient Balb/3T3 cells to ICRF-193, a catalytic inhibitor of DNA topoisomerase II
    Nishida, K
    Seto, M
    Ishida, R
    JAPANESE JOURNAL OF CANCER RESEARCH, 2001, 92 (02): : 193 - 202
  • [18] EFFECT OF ICRF-193, A NOVEL DNA TOPOISOMERASE-II INHIBITOR, ON SIMIAN VIRUS-40 DNA AND CHROMOSOME-REPLICATION INVITRO
    ISHIMI, Y
    ISHIDA, R
    ANDOH, T
    MOLECULAR AND CELLULAR BIOLOGY, 1992, 12 (09) : 4007 - 4014
  • [19] Decreased topoisomerase IIα expression confers increased resistance to ICRF-193 as well as VP-16 in mouse embryonic stem cells
    Kobayashi, M
    Adachi, N
    Aratani, Y
    Kikuchi, A
    Koyama, H
    CANCER LETTERS, 2001, 166 (01) : 71 - 77
  • [20] Differentiation of U-937 promonocytic cells by etoposide and ICRF-193, two antitumour DNA topoisomerase II inhibitors with different mechanisms of action
    Perez, C
    Vilaboa, NE
    GarciaBermejo, L
    deBlas, E
    Creighton, AM
    Aller, P
    JOURNAL OF CELL SCIENCE, 1997, 110 : 337 - 343
1234